264 related articles for article (PubMed ID: 29262329)
1. PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.
Chiang K; Zielinska AE; Shaaban AM; Sanchez-Bailon MP; Jarrold J; Clarke TL; Zhang J; Francis A; Jones LJ; Smith S; Barbash O; Guccione E; Farnie G; Smalley MJ; Davies CC
Cell Rep; 2017 Dec; 21(12):3498-3513. PubMed ID: 29262329
[TBL] [Abstract][Full Text] [Related]
2. PRMT5 and FOXP1 expression profile in invasive breast cancer patients undergoing neoadjuvant chemotherapy.
Su H; Liu Y; Zhang C; Yu T; Niu Y
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):142-145. PubMed ID: 32415941
[TBL] [Abstract][Full Text] [Related]
3. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
4. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
5. Protein arginine methyltransferase 5: a potential cancer therapeutic target.
Yuan Y; Nie H
Cell Oncol (Dordr); 2021 Feb; 44(1):33-44. PubMed ID: 33469838
[TBL] [Abstract][Full Text] [Related]
6. A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy.
Zhou Z; Feng Z; Hu D; Yang P; Gur M; Bahar I; Cristofanilli M; Gradishar WJ; Xie XQ; Wan Y
EBioMedicine; 2019 Jun; 44():98-111. PubMed ID: 31101597
[TBL] [Abstract][Full Text] [Related]
7. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
Chen H; Lorton B; Gupta V; Shechter D
Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
[TBL] [Abstract][Full Text] [Related]
8. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
Tarighat SS; Santhanam R; Frankhouser D; Radomska HS; Lai H; Anghelina M; Wang H; Huang X; Alinari L; Walker A; Caligiuri MA; Croce CM; Li L; Garzon R; Li C; Baiocchi RA; Marcucci G
Leukemia; 2016 Apr; 30(4):789-99. PubMed ID: 26536822
[TBL] [Abstract][Full Text] [Related]
9. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.
Zheng BN; Ding CH; Chen SJ; Zhu K; Shao J; Feng J; Xu WP; Cai LY; Zhu CP; Duan W; Ding J; Zhang X; Luo C; Xie WF
Theranostics; 2019; 9(9):2606-2617. PubMed ID: 31131056
[No Abstract] [Full Text] [Related]
10. CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.
Huang S; Chi Y; Qin Y; Wang Z; Xiu B; Su Y; Guo R; Guo L; Sun H; Zeng C; Zhou S; Hu X; Liu S; Shao Z; Wu Z; Jin W; Wu J
Theranostics; 2018; 8(9):2549-2564. PubMed ID: 29721098
[TBL] [Abstract][Full Text] [Related]
11. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
[TBL] [Abstract][Full Text] [Related]
12. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
13. Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer.
Wang X; Qiu T; Wu Y; Yang C; Li Y; Du G; He Y; Liu W; Liu R; Chen CH; Shi Y; Pan J; Zhou J; Jiang D; Chen C
Cell Death Differ; 2021 Oct; 28(10):2931-2945. PubMed ID: 33972717
[TBL] [Abstract][Full Text] [Related]
14. Protein arginine methyltransferase 5 (PRMT5) activates WNT/β-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3.
Shailesh H; Siveen KS; Sif S
J Cell Mol Med; 2021 Feb; 25(3):1583-1600. PubMed ID: 33462997
[TBL] [Abstract][Full Text] [Related]
15. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
[TBL] [Abstract][Full Text] [Related]
16. PRMT1 loss sensitizes cells to PRMT5 inhibition.
Gao G; Zhang L; Villarreal OD; He W; Su D; Bedford E; Moh P; Shen J; Shi X; Bedford MT; Xu H
Nucleic Acids Res; 2019 Jun; 47(10):5038-5048. PubMed ID: 30916320
[TBL] [Abstract][Full Text] [Related]
17. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
18. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
Alinari L; Mahasenan KV; Yan F; Karkhanis V; Chung JH; Smith EM; Quinion C; Smith PL; Kim L; Patton JT; Lapalombella R; Yu B; Wu Y; Roy S; De Leo A; Pileri S; Agostinelli C; Ayers L; Bradner JE; Chen-Kiang S; Elemento O; Motiwala T; Majumder S; Byrd JC; Jacob S; Sif S; Li C; Baiocchi RA
Blood; 2015 Apr; 125(16):2530-43. PubMed ID: 25742700
[TBL] [Abstract][Full Text] [Related]
20. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
Wang Z; Kong J; Wu Y; Zhang J; Wang T; Li N; Fan J; Wang H; Zhang J; Ling R
Breast Cancer Res Treat; 2018 Apr; 168(2):531-542. PubMed ID: 29185119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
